Debrisoquine

Debrisoquine^[1]
Names
	Preferred IUPAC name 3,4-Dihydroisoquinoline-2(1H)-carboximidamide
Identifiers
CAS Number	1131-64-2 ;
3D model (JSmol)	Interactive image;
ChEBI	CHEBI:34665 ;
ChEMBL	ChEMBL169901 ;
ChemSpider	2860 ;
DrugBank	DB04840 ;
ECHA InfoCard	100.013.155
KEGG	C13650 ;
MeSH	Debrisoquine
PubChem CID	2966;
UNII	X31CDK040E ;
CompTox Dashboard (EPA)	DTXSID7022885 ;
	InChI InChI=1S/C10H13N3/c11-10(12)13-6-5-8-3-1-2-4-9(8)7-13/h1-4H,5-7H2,(H3,11,12) Key: JWPGJSVJDAJRLW-UHFFFAOYSA-N ; InChI=1/C10H13N3/c11-10(12)13-6-5-8-3-1-2-4-9(8)7-13/h1-4H,5-7H2,(H3,11,12) Key: JWPGJSVJDAJRLW-UHFFFAOYAE;
	SMILES [N@H]=C(N)N2Cc1c(cccc1)CC2;
Properties
Chemical formula	C10H13N3
Molar mass	175.23032
Pharmacology
ATC code	C02CC04 (WHO)
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

Debrisoquine is a derivative of guanidine. It is an antihypertensive drug similar to guanethidine. Debrisoquine is frequently used for phenotyping the CYP2D6 enzyme, a drug-metabolizing enzyme.^[2]

Debrisoquine has been identified as a inhibitor of TMPRSS2 protease, which is involved in the viral entry process of SARS-CoV-2. In a laboratory study, it showed antiviral activity by blocking the ability of the virus to enter human lung cells.^[3]

The guanidine part of the molecule also appears in guanoxan and guanadrel.^{[citation needed]} The 7-bromo analog of debrisoquine is called guanisoquin.^{[citation needed]}

^ Debrisoquine – Compound Summary, PubChem.
^ Fuhr, U.; Jetter, A.; Kirchheiner, J. (2007). "Appropriate Phenotyping Procedures for Drug Metabolizing Enzymes and Transporters in Humans and Their Simultaneous Use in the "Cocktail" Approach". Clinical Pharmacology & Therapeutics. 81 (2): 270–283. doi:10.1038/sj.clpt.6100050. PMID 17259951.
^ Peiffer AL, Garlick JM, Wu Y, Wotring JW, Arora S, Harmata AS, Bochar DA, Stephenson CJ, Soellner MB, Sexton JZ, Brooks CL, Mapp AK (June 2023). "TMPRSS2 Inhibitor Discovery Facilitated through an In Silico and Biochemical Screening Platform". ACS Medicinal Chemistry Letters. 14 (6): 860–866. doi:10.1021/acsmedchemlett.3c00035. PMC 10237299. PMID 37284689.

[1] Debrisoquine – Compound Summary, PubChem.

[2] Fuhr, U.; Jetter, A.; Kirchheiner, J. (2007). "Appropriate Phenotyping Procedures for Drug Metabolizing Enzymes and Transporters in Humans and Their Simultaneous Use in the "Cocktail" Approach". Clinical Pharmacology & Therapeutics. 81 (2): 270–283. doi:10.1038/sj.clpt.6100050. PMID 17259951.

[pmid37284689-3] Peiffer AL, Garlick JM, Wu Y, Wotring JW, Arora S, Harmata AS, Bochar DA, Stephenson CJ, Soellner MB, Sexton JZ, Brooks CL, Mapp AK (June 2023). "TMPRSS2 Inhibitor Discovery Facilitated through an In Silico and Biochemical Screening Platform". ACS Medicinal Chemistry Letters. 14 (6): 860–866. doi:10.1021/acsmedchemlett.3c00035. PMC 10237299. PMID 37284689.

[1]

[2]

[3]

Debrisoquine

From Wikipedia, the free encyclopedia · View on Wikipedia